Clinical Trial Update: To Evaluate The Role of Intravitreal Aflibercept Injection (2.0 mg) in the Management of Previously Treated Patients With Exudative AMD [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating intravitreal aflibercept (2.0 mg) for previously treated exudative AMD with persistent or recurrent fluid.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• EYLEA (Aflibercept)

Snippet

Sponsor: Vitreous -Retina- Macula Consultants of New York | Conditions: AMD (With Persistent or Recurrent Fluid Despite Monthly Intravitreal Anti-VEGF Therapy) | Phase 4 | Status: COMPLETED | Results posted: 2018-09-07